drugset / Trial / NCT00171353

A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

NCT00171353

Phase 4 Completed 109 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.

Timeline

Start
2004-07
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Small molecule 160 mg

Indications